Home

Martin Babler

CIK 1435618 · President, CEO and Chairman · last filed 2026-06-25

Martin Babler is a President, CEO and Chairman who has filed 34 SEC Form 4 insider transactions across 8 companies since 2008. The most recent filing, for MPLT, was dated Jun 25, 2026. Across all open-market trades the lifetime net is −$3.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.1M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.11M

Companies

8

Total Filings

34

Lifetime Open-Market Net

-$3.34M

Filer Profile

Reported Address
C/O ALUMIS INC.
280 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
MPLT Director 7,864 $13.00 $102.2K $0 1 2026-06-25
PRLD Director — $4.59 — $0 6 2026-06-10
ALMS President, CEO and Chairman 109,454 $9.18 $1.00M $100.7K 5 2026-01-28
89bio, Inc. (ETNB) Delisted Director — $14.84 — $0 3 2025-10-30
Neurogene Inc. (NLTX) Delisted Director — $13.96 — $0 4 2023-06-09
Principia Biopharma Inc. (PRNB) Delisted President, CEO 0 — — -$3.45M 6 2020-09-28
ZS Pharma, Inc. (ZSPH) Delisted Director — — — $0 1 2015-06-25
INFINITY PHARMACEUTICALS, INC. (INFI) Delisted Director — $0.04 — $0 6 2013-06-13

Recent Filings

34 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-25 MPLT Grant (A) +7,864 $0 EDGAR
2026-06-10 PRLD Grant (A) — $0 EDGAR
2026-01-28 ALMS Grant (A) — $0 EDGAR
2025-10-30 89bio, Inc. (ETNB) Delisted Disp (D) — $0 EDGAR
2025-07-31 ALMS Grant (A) — $0 EDGAR
2025-06-13 PRLD Grant (A) — $0 EDGAR
2025-04-03 ALMS Buy (P) +15,650 $100.7K EDGAR
2025-02-20 ALMS Grant (A) — $0 EDGAR
2025-02-05 89bio, Inc. (ETNB) Delisted Grant (A) — $0 EDGAR
2024-07-01 ALMS Mixed — $0 EDGAR
Showing 1–10 of 34
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.